Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities
Open Access
- 16 December 2014
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 5, 478
- https://doi.org/10.3389/fphys.2014.00478
Abstract
GTPases and kinases are two predominant signaling modules that regulate cell fate. Dysregulation of Ras, a GTPase, and the three eponymous kinases that form key nodes of the associated phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K)/AKT/mTOR pathway have been implicated in many cancers, including pancreatic cancer, a disease noted for its current lack of effective therapeutics. The K-Ras isoform of Ras is mutated in over 90% of pancreatic ductal adenocarcinomas (PDAC) and there is growing evidence linking aberrant PI3K/AKT/mTOR pathway activity to PDAC. Although these observations suggest that targeting one of these nodes might lead to more effective treatment options for patients with pancreatic and other cancers, the complex regulatory mechanisms and the number of sequence-conserved isoforms of these proteins have been viewed as significant barriers in drug development. Emerging insights into the allosteric regulatory mechanisms of these proteins suggest novel opportunities for development of selective allosteric inhibitors with fragment-based drug discovery helping make significant inroads. The fact that allosteric inhibitors of Ras and AKT are currently in pre-clinical development lends support to this approach. In this article, we will focus on the recent advances and merits of developing allosteric drugs targeting these two inter-related signaling pathways.Keywords
This publication has 59 references indexed in Scilit:
- Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated ActivationAngewandte Chemie-International Edition, 2012
- Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinasesOncogene, 2011
- Dynamics of the Phosphoinositide 3-Kinase p110δ Interaction with p85α and Membranes Reveals Aspects of Regulation Distinct from p110αStructure, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory MechanismMolecular Cell, 2011
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- Inhibitor hijacking of Akt activationNature Chemical Biology, 2009
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994